Latin America Epilepsy Drugs Market Size & Outlook
Related Markets
Latin America epilepsy drugs market highlights
- The Latin America epilepsy drugs market generated a revenue of USD 536.6 million in 2024.
- The market is expected to grow at a CAGR of 4.6% from 2025 to 2030.
- In terms of segment, first generation anti-epileptics was the largest revenue generating product in 2024.
- Second Generation Anti-epileptics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Argentina is expected to register the highest CAGR from 2025 to 2030.
Latin America data book summary
| Market revenue in 2024 | USD 536.6 million |
| Market revenue in 2030 | USD 700.2 million |
| Growth rate | 4.6% (CAGR from 2025 to 2030) |
| Largest segment | First generation anti-epileptics |
| Fastest growing segment | Second Generation Anti-epileptics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics |
| Key market players worldwide | UCB SA, Sanofi SA, Pfizer Inc, Otsuka Pharmaceutical, Eisai Co Ltd, Abbott Laboratories, Novartis AG ADR, GlaxoSmithKline, Sumitomo Pharma Co Ltd, Neurelis, Jazz Pharmaceuticals PLC |
Other key industry trends
- In terms of revenue, Latin America region accounted for 4.8% of the global epilepsy drugs market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,181.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Epilepsy Drugs Market Scope
Epilepsy Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | View profile | 2800 | Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, Ireland, D04 E5W7 | https://www.jazzpharmaceuticals.com |
| Sumitomo Pharma Co Ltd | View profile | 6250 | 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Japan, 541-0045 | https://www.sumitomo-pharma.com |
| Neurelis | View profile | 101-250 | Encinitas, California, United States, North America | http://www.neurelis.com/ |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Eisai Co Ltd | View profile | 11076 | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan, 112-8088 | http://www.eisai.co.jp |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | https://www.otsuka.co.jp/en/ |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Latin America epilepsy drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epilepsy drugs market will help companies and investors design strategic landscapes.
First generation anti-epileptics was the largest segment with a revenue share of 41.48% in 2024. Horizon Databook has segmented the Latin America epilepsy drugs market based on first generation anti-epileptics, second generation anti-epileptics, third generation anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Latin America epilepsy drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Latin America epilepsy drugs market databook
-
Our clientele includes a mix of epilepsy drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America epilepsy drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America epilepsy drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Latin America epilepsy drugs market size, by country, 2018-2030 (US$M)
Latin America Epilepsy Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
